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MaBACKGROUND Considerable uncertainty exists as to whether lowering low-density lipoprotein cholesterol (LDL-C) by
inhibiting the Niemann-Pick C1-Like 1 (NPC1L1) receptor with ezetimibe, either alone or in combination with a 3-hydroxy-
3-methylglutaryl-coenzyme A reductase (HMGCR) inhibitor (statin), will reduce the risk of coronary heart disease (CHD).
OBJECTIVES This study evaluated the effect of naturally random allocation to lower LDL-C mediated by polymor-
phisms in the NPC1L1 gene (target of ezetimibe), the HMGCR gene (target of statins), or both (target of combination
therapy) on the risk of CHD.
METHODS We constructed NPC1L1 and HMGCR genetic LDL-C scores to naturally randomize participants into 4 groups:
reference, lower LDL-C mediated by NPC1L1 polymorphisms, lower LDL-C mediated by HMGCR polymorphisms, or lower
LDL-C mediated by polymorphisms in both NPC1L1 and HMGCR. We compared the risk of CHD (fatal or nonfatal
myocardial infarction) among each group using a 2  2 factorial mendelian randomization study design.
RESULTS A total of 108,376 persons (10,464 CHD events) from 14 studies were included. There were no signiﬁcant
differences in baseline characteristics among the 4 groups, thus conﬁrming that allocation was random. Compared to the
reference group, the NPC1L1 group had 2.4 mg/dl lower LDL-C and 4.8% lower risk of CHD (odds ratio [OR]: 0.952, 95%
conﬁdence interval [CI]: 0.920 to 0.985); whereas the HMGCR group had 2.9 mg/dl lower LDL-C and a similar 5.3%
lower risk of CHD (OR: 0.947, 95% CI: 0.909 to 0.986). The group with lower LDL-C mediated by both NPC1L1 and
HMGCR polymorphisms had 5.8 mg/dl additively lower LDL-C and a 10.8% log-linearly additive lower risk of CHD
(OR: 0.892, 95% CI: 0.854 to 0.932).
CONCLUSIONS The effect of lower LDL-C on the risk of CHD mediated by polymorphisms in NPC1L1, HMGCR, or both
is approximately the same per unit lower LDL-C and log-linearly proportional to the absolute exposure to lower LDL-C.
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1553AB BR E V I A T I O N S
AND ACRONYM S
CHD = coronary heart disease
HMGCR = 3-hydroxy-3-
methylglutaryl-coenzyme
A reductase
LDL-C = low-density
lipoprotein cholesterol
MI = myocardial infarction
NPC1L1 = Niemann-Pick
ke 1M eta-analyses of prospective epidemiologiccohort studies (1,2) and meta-analyses ofmendelian randomization genetic studies
(3) have shown a consistent, causal, and log-linear
association between low-density lipoprotein choles-
terol (LDL-C) and the risk of coronary heart disease
(CHD). Additionally, meta-analyses of numerous ran-
domized controlled trials have shown that lowering
LDL-C by inhibiting 3-hydroxy-3-methyl-glutaryl-
coenzyme A reductase (HMGCR) with a statin re-
duces the risk of CHD and other major vascular
events (4). Despite the established causal associa-
tion between LDL-C and the risk of CHD, several ran-
domized trials have failed to consistently show an
incremental clinical beneﬁt from further lowering
LDL-C by adding niacin or a ﬁbrate to treatment
with a statin (5–7), creating uncertainty as to
whether lowering LDL-C by a mechanism other
than inhibiting HMGCR with a statin will reduce
the risk of CHD.SEE PAGE 1562Ezetimibe is a commonly prescribed medication
that effectively lowers LDL-C when used alone or
when added to treatment with statin. Importantly,
both ezetimibe and statins lower LDL-C through a
common ﬁnal pathway. Ezetimibe inhibits intestinal
absorption of cholesterol by binding to the Niemann-
Pick C1-Like 1 (NPC1L1) protein, which leads to up-
regulation of hepatic LDL-C receptors and increased
clearance of circulating LDL-C (8). Similarly, statins
reduce hepatic cholesterol synthesis by inhibiting
HMGCR, which leads to up-regulation of hepatic
LDL-C receptors and increased clearance of circu-
lating LDL-C. Because both ezetimibe and statins
reduce LDL-C through the same ﬁnal common
pathway, it is intuitive to hypothesize that lowering
LDL-C by inhibiting NPC1L1 with ezetimibe may also
reduce the risk of CHD and other major vascular
events. IMPROVE-IT (IMProved Reduction of Out-
comes: Vytorin Efﬁcacy International Trial) is testing
this hypothesis (9,10).
To compare the biological effect of lower LDL-C
mediated by inhibition of NCP1L1, HMGCR, or
both on the risk of CHD, and to provide a context
for interpreting the results of IMPROVE-IT, we
sought to compare the effect of naturally random
allocation to lower LDL-C on the risk of CHD
mediated by genetic polymorphisms in the NPC1L1
gene (as a proxy for ezetimibe treatment), the
HMGCR gene (as a proxy for statin treatment),
or both (as a proxy for combination treatment) using
a novel 2  2 factorial mendelian randomization
study design.METHODS
Our study included 108,376 total persons
from 14 prospective cohort or case-control
studies who provided written informed con-
sent for genetic studies and with individual-
level data available as part of the National
Center for Biotechnology Information data-
base of Genotypes and Phenotypes program
(11). Online Table S1 describes the included
studies. As part of a larger project, we ﬁrst
harmonized the deﬁnition of all cardiovascular-
related exposure and outcome variables across the
14 studies, and then recoded individual-level data
for each study subject as necessary to satisfy the
harmonized variable deﬁnitions. The primary out-
come for this study was CHD, deﬁned as the ﬁrst
occurrence of CHD death or a nonfatal myocardial
infarction (MI). Among subjects with available ge-
netic information enrolled in the 14 studies, 10,464
ﬁrst CHD outcome events occurred, all of which were
included in the primary analysis.
We ﬁrst constructed NPC1L1 and HMGCR genetic
LDL-C scores to create an instrument that could
overcome the weak effect of most NPC1L1 and
HMGCR polymorphisms on plasma LDL-C levels
(12–14), and that would also allow us to randomly
allocate study subjects into approximately equal-
sized groups to facilitate the 2  2 factorial anal-
ysis. We constructed the genetic LDL-C scores by
identifying all polymorphisms in or within 100 kb on
either side of the NPC1L1 and HMGCR genes,
respectively, that were associated with LDL-C at a
threshold of p < 5.0  10-6, as measured in up to
183,465 persons of European descent in the Global
Lipids Genetic Consortium (GLGC) (12). We then
ranked the polymorphisms in each gene by the re-
ported p value and iteratively selected all approxi-
mately independently inherited polymorphisms,
deﬁned by a low degree of linkage disequilibrium
(r2 < 0.30 for all comparisons), to include in each
gene’s LDL-C score. Depending on the genotyping
platform used in each study, we used the selected
polymorphism or its nearest proxy. If a close proxy
(r2 $ 0.95) was not available, we imputed genotypes
for the selected polymorphism for all members of
that study population using the 1000 Genomes
reference panel (15). A total of 5 approximately in-
dependent polymorphisms were included in the
NPC1L1 genetic LDL-C score, and 3 were included in
the HMGCR genetic LDL-C score (Online Tables S2
to S7). For each selected polymorphism, we coded
the exposure allele as the allele associated with
lower LDL-C.
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1554For each study subject, we calculated a weighted
NPC1L1 and HMGCR genetic LDL-C score by summing
the number of LDL-Clowering alleles inherited at
each of the polymorphisms included in either score,
weighted by its effect on LDL-C measured in
mg/dl (as estimated in the GLGC) (12). Because each
polymorphism included in either genetic score is
inherited approximately randomly at conception and
approximately independently of the other poly-
morphisms included in each score, the number of
LDL-Clowering alleles that a person inherits in
either score should also be random.
To conduct the 2  2 factorial analyses, we ﬁrst
dichotomized each genetic LDL-C score as above or
below the median value for that score (as measured
in the study population). Next, study subjects were
naturally randomly allocated into 2 groups, depend-
ing on whether their HMGCR genetic LDL-C scoreFIGURE 1 Design of 2  2 Factorial Mendelian Randomization Study
HMGCR LDL
NPC1L1 LDL–C score
Lower LDL–C
via NPC1L1
Ezetimibe
Proxy for trea
naturally randomize
naturally ran
Placebo
Below Median
(reference)
Reference
Below Median
(reference)
Above Median
(Lower LDL–C)
Lifetime Risk of
Each subject was ﬁrst randomly allocated into 1 of 2 groups based on wh
then randomly allocated into 1 of 2 further groups based on whether thei
design. This process naturally randomized all subjects into 1 of 4 group
lower LDL-C mediated polymorphisms in the NPC1L1 gene (analogous to
polymorphisms in the HMGCR gene (analogous to treatment with a stat
of polymorphisms in both the NPC1L1 and HMGCR genes (analogous towas above or below the median. Subjects in each of
these 2 groups were then randomly allocated into 2
further groups, depending on whether their NPC1L1
genetic LDL-C score was above or below the median.
This process naturally randomized all subjects into
1 of 4 groups (Figure 1): the reference group (analo-
gous to a placebo group), a group with lower LDL-C
mediated by NPC1L1 polymorphisms (analogous to
ezetimibe treatment), a group with lower LDL-C
mediated by HMGCR polymorphisms (analogous to
statin treatment), and a group with lower LDL-C
mediated by the combined effect of polymorphisms
in the both the NPC1L1 and HMGCR genes (analogous
to treatment with a combination of ezetimibe and
a statin).
We assessed the success of the naturally random
allocation scheme by comparing baseline character-
istics among subjects in each of the 4 groups. We–C score
NPC1L1 LDL–C score
Lower LDL–C via
NPC1L1 & HMGCR
Lower LDL–C
via HMGCR
tment with:
domize
naturally randomize
Statin Ezetimibe/Statin
Below Median
(reference)
Above Median
(Lower LDL–C)
Above Median
(Lower LDL–C)
 CHD events
ether their HMGCR LDL-C score was above or below the median, and
r NPC1L1 LDL-C score was above or below the median using a factorial
s: the reference group (analogous to a placebo group), a group with
treatment with ezetimibe), a group with lower LDL-C mediated
in), and a group with lower LDL-C mediated by the combined effect
treatment with combination ezetimibe and a statin).
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group and the reference group using linear regres-
sion and the risk of CHD in each group compared
with the reference group using logistic regression
(for combined prevalent and incident events) or Cox
proportional hazard models (for incident events),
adjusted for age and sex. All analyses were per-
formed separately in each of the 14 included
study samples, and then combined across studies in
a ﬁxed-effects inverse variance-weighted meta-
analysis to produce summary estimates of effect. To
minimize potential population stratiﬁcation bias,
separate analyses were performed for each included
racial group.
To provide external validation, we compared the
effect of lower LDL-C on the risk of CHD mediated by
the NPC1L1 and HMGCR genetic LDL-C scores in up
to 62,240 cases and 127,299 control subjects enrolled
in the CARDIoGRAM or CARDIoGRAMplusC4D con-
sortia studies (16). To calculate these scores using
available summary data, we looked up the association
between each polymorphism included in the NPC1L1
and HMGCR genetic LDL-C scores and the CHD risk, as
reported by the CARDIoGRAMplusC4D consortium
(17). We adjusted the reported effect size (and corre-
sponding standard error) by the effect of that poly-
morphism on LDL-C (in mg/dl), as reported by the
GLGC (12), using the usual ratio of effect estimates
method. We then combined the adjusted effect esti-
mates in a ﬁxed-effects inverse variance-weightedTABLE 1 Baseline Characteristics
Characteristic Reference Group
NPC1L1 LDL-C Score
Above Median
Sample size 27,744 28,611
LDL-C, mg/dl 132.5  31.8 130.1  33.1
Age, yrs 59.4  6.3 59.1  6.7
Males 43.6 44.1
Weight, lbs 166.5  35.8 165.2  36.5
BMI, kg/m2 27.2  5.4 27.9  5.7
HDL-C, mg/dl 51.8  14.7 51.0  14.8
TG, mg/dl 135.3 (78-158) 134.4 (77-161)
Lipid treatment 4.9 4.7
SBP, mm Hg 125.8  16.4 125.1  16.1
DBP, mm Hg 73.9  11.2 74.2  10.8
BP treatment 36.1 37.8
Current smoker 12.8 12.5
Former smoker 32.1 30.9
Diabetes 6.3 6.6
Values are n, mean SD, %, or median (interquartile range). Sample size includes all subje
values measured at baseline study visit among subjects enrolled in the prospective cohor
variables were compared with either one-way analysis of variance for normally distribut
BMI ¼ body mass index; BP ¼ blood pressure; DBP ¼ diastolic blood pressure;
coenzyme A reductase; LDL-C ¼ low-density lipoprotein cholesterol; NPC1L1 ¼ Niema
TG ¼ triglycerides.meta-analysis to produce NPC1L1 and HMGCR ge-
netic LDL scores that represent a summary estimate
of the effect of each unit lower LDL-C on the risk of
CHD mediated by the combined effect of the poly-
morphisms included in either genetic LDL-C score.
All statistical analyses used a 2-tailed p < 0.05
threshold for nominal statistical signiﬁcance and all
analyses were performed using STATA 12 (StataCorp,
LP, College Station, Texas), SNP & Variation Suite
(Version 8.1.4; Golden Helix, Bozeman, Montana), or
IMPUTE2 (18,19). The Online Appendix provides a
detailed description of the methods.
RESULTS
ASSOCIATION BETWEEN GENETIC LDL-C SCORES,
PLASMA LDL-C LEVELS, AND RISK OF CHD. There
were no signiﬁcant differences in any baseline char-
acteristics between the 4 groups (Table 1), showing
that allocation was indeed random. The apparently
random allocation of study subjects into approxi-
mately equal-sized groups also internally validates
the use of the NPC1L1 and HMGCR LDL-C scores as
instrumental variables.
The mean age of study subjects was 59 years, only
4.8% were taking a lipid-lowering therapy at baseline,
and the mean baseline LDL-C level was 132.5 mg/dl
among persons in the reference group (Table 1).
Compared with the reference group (both NPC1L1 and
HMGCR scores below the median), persons in theHMGCR LDL-C Score
Above Median
Both LDL-C Scores
Above Median p Value
25,577 26,444
129.6  32.7 126.7  32.3 2.3  10-47
58.9  6.1 59.6  5.9 NS
43.3 43.9 NS
165.9  36.2 167.4  35.4 NS
27.1  5.1 27.7  4.9 NS
51.7  14.2 51.2  15.1 NS
134.9 (81-164) 135.3 (79-156) NS
5.1 4.6 NS
126.0  17.5 125.7  16.8 NS
74.3  11.6 73.7  11.0 NS
36.5 36.9 NS
13.3 12.7 NS
31.4 32.6 NS
6.0 5.9 NS
cts in both the prospective cohort and case-control studies. Clinical characteristics are
t studies. Categorical variables were compared with a chi-square test, and continuous
ed variables or the Kruskal-Wallis test for non-normally distributed variables.
HDL-C ¼ high-density lipoprotein cholesterol; HMGCR ¼ hydroxymethyl glutaryl
nn-Pick C1-Like 1; NS ¼ not signiﬁcant (p > 0.05); SBP ¼ systolic blood pressure;
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1556group with an NPC1L1 genetic LDL-C score above the
median (and an HMGCR score below the median) had
2.4 mg/dl lower LDL-C and a signiﬁcant 4.8% lower
risk of CHD (odds ratio [OR]: 0.952, 95% conﬁdence
interval [CI]: 0.920 to 0.985; p ¼ 4.4  10-3).
Compared with the reference group, persons in the
group with an HMGCR genetic LDL-C score above the
median (and an NPC1L1 score below the median) had
2.9 mg/dl lower LDL-C and a similar 5.3% lower
risk of CHD (OR: 0.947, 95% CI: 0.909 to 0.986;
p ¼ 9.1  10-3). There was no signiﬁcant difference in
either LDL-C level or risk of CHD among persons with
NPC1L1 scores above the median, as compared with
persons with HMGCR LDL-C scores above the median
(p ¼ 0.84). Compared with the reference group, per-
sons in the group with both NPC1L1 and HMGCR ge-
netic LDL-C scores above the median had 5.8 mg/dl
lower LDL-C and a 10.8% lower risk of CHD (OR:
0.892, 95% CI: 0.854 to 0.932; p ¼ 2.5  10-7). The
combination of both NPC1L1 and HMGCR poly-
morphisms was associated with a linearly additive
effect on plasma LDL-C levels and a log-linearly ad-
ditive effect on CHD risk (Figure 2). The CHD risk was
signiﬁcantly lower in the group with NPC1L1 and
HMGCR scores above the median as compared with
both the group with NPC1L1 scores above the median
(p ¼ 0.045) and the group with HMGCR scores above
the median (p ¼ 0.021).FIGURE 2 Effect of Lower LDL-C Mediated by Polymorphisms in NP
–2.9 (–2.4,–3.4)
–5.8 (–5.3,–6.3)Both NPC1L1 & HMGCR
LDL–C Scores above
median
Group
LDL–C Effect
Size mg/dl
(95% CI)
NPC1L1 LDL–C Score
above median
HMGCR LDL–C Score
above median
–2.4 (–1.9,–2.9)
0.85
Boxes represent point estimates and lines represent 95% CIs. Reference
median. CI ¼ conﬁdence interval; LDL-C ¼ low-density lipoprotein chol
NPC1L1 ¼ Niemann-Pick C1-Like 1.To further compare the effect of lower LDL-C
mediated by NPC1L1 and HMGCR polymorphisms,
we also evaluated the effect of each genetic LDL-C
score in the entire study population (without further
partitioning into smaller groups by the other genetic
LDL-C score, as occurs in 2  2 factorial analysis).
Compared with persons with NPC1L1 genetic LDL-C
scores below the median, persons with scores above
the median had 2.3 mg/dl lower LDL-C (p ¼ 8.2  10-12)
and a 4.4% lower risk of CHD (OR: 0.956, 95% CI:
0.930 to 0.983; p ¼ 1.3  10-3). Similarly, compared
with persons with HMGCR genetic LDL-C scores
below the median, persons with scores above the me-
dian had 3.0 mg/dl lower LDL-C (p ¼ 3.7  10-17) and a
5.2% lower risk of CHD (OR: 0.948, 95% CI: 0.920 to
0.977; p ¼ 4.8  10-4). These results were essentially
unchangedwhenmodeling the genetic LDL-C scores as
continuous variables. In these analyses, the effect of
lower LDL-C on the risk of CHD mediated by NPC1L1
and HMGCR polymorphisms was very similar per unit
lower LDL-C. When both genetic LDL-C scores were
included in the same model, each score’s effect
remained essentially unchanged, with no evidence for
any effect modiﬁcation on either plasma LDL-C levels
or CHD risk in models that included an interaction
term.
EXTERNAL VALIDATION ANALYSES. In external
validation analyses involving up to 62,240 cases ofC1L1, HMGCR, or Both
0.952 (0.920–0.985)
p = 4.4x10-3
0.947 (0.909–0.986)
p = 9.1x10-3
ORCHD (95% CI)
0.90 0.95 1.0
0.892 (0.854–0.932)
p = 2.5x10-7
group is the group with both NPC1L1 and HMGCR LDL-C scores below
esterol; HMGCR ¼ hydroxymethyl glutaryl coenzyme A reductase;
FIGURE 3 Comparison of Effect of 10 mg/dl Lower LDL-C on Risk of CHD Mediated
by Polymorphisms in the NPC1L1 and HMGCR Genetic LDL-C Scores in Up to
62,240 Cases of CHD and 127,299 Control Subjects
Genetic LDL–C Score
HMGCR LDL–C Score 0.828 (0.775–0.885)
p = 5.5x10-8
ORCHD (95% CI)
Adjusted  per 10 mg/dl LDL–C
0.823 (0.741–0.915)
p = 3.1x10-4
NPC1L1 LDL–C Score
1.00.900.800.70
Boxes represent point estimates and lines represent 95% CIs. Abbreviations as in Figure 2.
J A C C V O L . 6 5 , N O . 1 5 , 2 0 1 5 Ference et al.
A P R I L 2 1 , 2 0 1 5 : 1 5 5 2 – 6 1 LDL Cholesterol and NPC1L1, HMGCR Polymorphisms
1557CHD and 127,299 control subjects, each 10 mg/dl
lower LDL-C mediated by polymorphisms in the
NPC1L1 genetic LDL-C score was associated with a
highly signiﬁcant 17.7% lower risk of CHD (OR: 0.823,
95% CI: 0.741 to 0.915; p ¼ 3.1  10-4) (Online
Figures S1A and S1B). Similarly, each 10 mg/dl lower
LDL-C mediated by polymorphisms in the HMGCR
genetic LDL-C score was associated with a similar and
highly signiﬁcant 17.2% lower risk of CHD (OR: 0.828,
95% CI: 0.775 to 0.885; p ¼ 5.5  10-8) (Online
Figures S2A and S2B). There was no signiﬁcant dif-
ference in the effect of lower LDL-C on the risk of CHD
mediated by NPC1L1 and HMGCR polymorphisms
when measured per unit lower LDL-C (p ¼ 0.93)
(Figure 3). These data appear to externally validate
the ﬁnding in our primary analysis that the effect of
lower LDL-C on the risk of CHD mediated by NPC1L1
and HMGCR genetic polymorphisms appears to be
approximately the same per unit lower LDL-C.
In additional external validation analyses in-
volving up to 63,746 cases of CHD and 130,681 control
subjects, we compared the effect of lower LDL-C
mediated by NPC1L1 and HMGCR gene poly-
morphisms and the NPC1L1 and HMGCR genetic
scores with the effect of lower LDL-C mediated by
polymorphisms in other genes that lower circulating
LDL-C through the common ﬁnal pathway involving
the hepatic LDL-C receptor. This analysis included
both common and rare polymorphisms in the pro-
protein convertase subtilisin/kexin type 9 gene
(PCSK9). The effect of lower LDL-C on the risk of CHD
mediated by each of these polymorphisms was very
similar per unit lower LDL-C, with no evidence for
any signiﬁcant heterogeneity, as shown in Figure 4
(Online Tables S8 to S10, Online Figures S3 to S5).
Furthermore, when each polymorphism’s (or genetic
LDL-C score’s) effect on LDL-C was plotted against its
effect on CHD risk, there appeared to be a log-linear
relationship between the absolute magnitude of
exposure to lower LDL-C and the proportional
reduction in the risk of CHD, independent of the
mechanism by which LDL-C was lowered (Central
Illustration).
DISCUSSION
We appealed to the principle of mendelian randomi-
zation (20) to evaluate the effect of naturally random
allocation to lower LDL-C on the risk of CHD mediated
by polymorphisms in the NPC1L1 gene (the target of
ezetimibe), the HMGCR gene (the target of statins), or
both (the target of combination therapy with ezeti-
mibe and a statin) using a 2  2 factorial study design.
We conﬁrmed that allocation to lower LDL-C wasrandom by showing that there were no signiﬁcant
differences in any baseline characteristics between
the groups. Therefore, our results should provide an
unconfounded estimate of the causal effect of lower
LDL-C mediated by inhibition of NPC1L1, HMGCR, or
both on the risk of CHD in a manner analogous to a
2  2 factorial randomized trial comparing the effect
of treatment with ezetimibe, a statin, or both.
We found that lower LDL-C mediated by common
polymorphisms in the NPC1L1 gene is causally asso-
ciated with a lower CHD risk. This ﬁnding was
independently externally validated by a recent
report that rare NPC1L1 loss-of-function mutations
are also associated with both lower LDL-C and a
lower risk of CHD (21). Importantly, because we used
a 2  2 factorial study design, we could directly
compare the effect of lower LDL-C on CHD risk
mediated by the separate and combined effects of
NPC1L1 and HMGCR polymorphisms. We found
that NPC1L1 and HMGCR polymorphisms have
approximately the same effect on CHD risk when
measured per unit lower LDL-C. Furthermore, when
present together, NPC1L1 and HMGCR genetic poly-
morphisms appear to have independent, linearly
additive effects on plasma LDL-C levels and log-
linearly additive effects on CHD risk. These ﬁndings
strongly suggest that there is no difference in the
biological effect of lower LDL-C on the risk of
CHD mediated by inhibition of NPC1L1 or HMGCR.
Therefore, our results imply that lowering LDL-C
by inhibiting NPC1L1 with ezetimibe, inhibiting
HMGCR with a statin, or inhibiting both with the
combination of ezetimibe and a statin should each
lower the risk of CHD by approximately the same
amount per unit lower LDL-C, and that the magni-
tude of the clinical beneﬁt will be proportional to the
FIGURE 4 Comparison of Effect of 10 mg/dl Lower LDL-C on Risk of CHD Mediated by Polymorphisms in the LDL-C Receptor Pathway
in Up to 63,746 Cases of CHD and 130,681 Control Subjects
NPC1L1
Gene SNP LDL–C ES(mg/dl)
NPC1L1
HMGCR
HMGCR
PCSK9
PCSK9
PCSK9 (46L)
ABCG5/G8
LDL–R
LDL–C Score
rs217386 – 1.12 0.87 (0.74–1.02)
ORCHD (95% CI)
Adjusted per 10 mg/dl LDL–C
0.82 (0.74–0.91)
0.84 (0.78–0.91)
0.83 (0.75–0.92)
0.81 (0.73–0.89)
0.82 (0.74–0.90)
0.81 (0.74–0.88)
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Boxes represent point estimates and lines represent 95% CIs. Point estimates (and CI) adjusted per unit lower LDL-C using the usual
ratio of effect estimates method.
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1558absolute magnitude of the achieved reduction in
LDL-C, regardless of which treatment is used.
Indeed, our results agree closely with the recently
reported results of IMPROVE-IT (22), in which
addition of ezetimibe to treatment with simvastatin
resulted in a further mean LDL-C reduction of
15.8 mg/dl and a corresponding 6.4% reduction in
the primary composite endpoint of cardiovascular
death, MI, stroke, coronary revascularization, or
hospitalization for unstable angina (p ¼ 0.016); and
a 10.0% reduction in the composite endpoint of
cardiovascular death, nonfatal MI, or nonfatal stroke
(p ¼ 0.003). The magnitude of this risk reduction is
consistent with the effect size expected for a similar
reduction in LDL-C during statin treatment, as
estimated by the Cholesterol Treatment Trialists’
Collaboration meta-analysis of statin trials (4).
Therefore, the results of IMPROVE-IT suggest that
lowering LDL-C by inhibiting NPC1L1 with ezetimibe
has approximately the same effect on CHD risk as
inhibiting HMGCR with a statin, when measured
per unit lower LDL-C, and that combined NPC1L1
and HMGCR inhibition has independent and additive
effects on both plasma LDL-C levels and the corre-
sponding risk of CHD, as anticipated by the naturally
randomized genetic evidence in our study.The close agreement between our study’s results
and those of IMPROVE-IT substantially increases
conﬁdence in the validity of our ﬁndings. It also
suggests that it may be reasonable to appeal to the
naturally randomized genetic evidence to address
questions not speciﬁcally tested in IMPROVE-IT; for
example, whether the combination of a moderate-
dose statin plus ezetimibe will be as effective at
reducing the risk of CHD as treatment with a high-
dose statin. We found that the effect of lower LDL-C
mediated solely by HMGCR gene polymorphisms
had approximately the same effect on CHD risk as did
the effect of lower LDL-C mediated by the combined
effect of polymorphisms in both the HMGCR and
NPC1L1 genes, when measured per unit lower LDL-C.
Therefore, the naturally randomized genetic evidence
suggests that the use of a moderate-dose statin plus
ezetimibe should be a reasonable alternative to high-
dose statin therapy, particularly among persons un-
able or unwilling to take a high-dose statin, because
the effect of lower LDL-C on the risk of CHD appears
to be independent of the mechanism by which LDL-C
is lowered.
To further challenge our ﬁnding that the effect of
lower LDL-C on the risk of CHD appears independent
of the mechanism by which LDL-C is lowered, we
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Boxes represent proportional risk reduction (1–OR) of CHD for each exposure allele, genetic score, or randomized trial plotted against the absolute magnitude of lower
LDL-C associated with that allele or genetic score; or the absolute difference in LDL-C between treatment groups for each trial. Vertical lines represent 1 SE above and
below point estimate of proportional risk reduction. SNPs, genetic scores, and trials are plotted in order of increasing absolute magnitude of effect on lower LDL-C.
The lines (which are forced to pass through the origin) represent the increase in proportional risk reduction of CHD per unit lower LDL-C. In the top line, the
salmon boxes represent results of the 2  2 factorial mendelian randomization study and the blue boxes represent results derived from CARDIoGRAMplusC4D consortia
data. In the lower line, the salmon box represents the results of the IMPROVE-IT trial and the blue boxes represent the results of prior statin trials. CHD ¼ coronary
heart disease; IMPROVE-IT ¼ IMProved Reduction of Outcomes: Vytorin Efﬁcacy International Trial; LDL-C ¼ low-density lipoprotein cholesterol; OR ¼ odds ratio;
SE ¼ standard error; SNP ¼ single-nucleotide polymorphism.
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1559compared the effect of polymorphisms in multiple
different genes, each of which acts to lower LDL-C
through the common ﬁnal pathway of the hepatic
LDL-C receptor. This analysis not only included
NPC1L1 and HMGCR polymorphisms, but also both
common and rare polymorphisms in the PCSK9 gene
(which encodes the target of a new class of LDL-C-
lowering therapy under active investigation) (23).
We found that each of these polymorphisms had
a remarkably similar effect on CHD risk when
measured per unit lower LDL-C (Figure 4). Together,
these data strongly suggest that the effect of lower
LDL-C on the risk of CHD appears to be independent
of the mechanism by which LDL-C is lowered, at
least among pathways involving the LDL-C receptoras the ﬁnal common LDL-Clowering mechanism.
Instead, the clinical beneﬁt of exposure to both
genetically and pharmacologically mediated lower
LDL-C appears to be largely determined by the
absolute magnitude of exposure to lower LDL-C
(Central Illustration). These ﬁndings are consistent
with the results of prior mendelian randomization
studies (3,24), and may explain why treatment with
niacin or a ﬁbrate has failed to consistently reduce
the risk of CHD when added to a statin in random-
ized trials. In these trials, the absolute magnitude of
the difference in LDL-C between the 2 treatment
arms was very small, and likely too small to translate
into a numerically stable reduction in the risk of
CHD (5–7).
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Ob-
servations based upon mendelian randomization sug-
gests that the clinical beneﬁt of lower LDL-C levels
may be more closely related to the magnitude of
reduction than to the mechanism of LDL-C lowering.
TRANSLATIONAL OUTLOOK: Further studies us-
ing the natural genetic randomization of factors that
govern blood lipid metabolism may provide informa-
tion adjunctive to that from randomized clinical trials.
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1560STUDY LIMITATIONS. Our study has several limita-
tions. We measured the effect of lower LDL-C medi-
ated by polymorphisms in the NPC1L1 and HMGCR
genes, not the effect of lower LDL-C mediated by
treatment with ezetimibe and a statin. The effect of
treatments designed to inhibit NPC1L1 and HMGCR
may not have the same effect as polymorphisms in
the genes encoding the targets of these treatments.
However, numerous prior studies have shown that
adding ezetimibe to treatment with a statin further
reduces LDL-C by approximately 15% to 20%, inde-
pendent of the dose or type of statin used (25). This is
consistent with our ﬁnding that combined genetic
polymorphisms in the NPC1L1 and HMGCR genes are
associated with a linearly additive exposure to
lower LDL-C. More importantly, the close agreement
between the results of our study and those of
IMPROVE-IT suggests that genetically lower LDL-C
mediated by polymorphisms in the NPC1L1 and
HMCGR genes are reasonable proxies for treatment
with ezetimibe and a statin. Additionally, our study
found that lifetime exposure to small differences in
LDL-C mediated by NPC1L1 and HMGCR poly-
morphisms was associated with much larger than
expected reductions in the risk of CHD than would
be predicted by quantitatively similar reductions in
LDL-C observed in the statin trials or the IMPROVE-
IT trial. This ﬁnding is, however, consistent with
prior mendelian randomization studies that showed
that long-term exposure to lower LDL-C appears to
have a cumulative effect on the risk of CHD and is
associated with up to a 3-fold greater reduction in
the risk of CHD per unit lower LDL-C, as compared
to short-term treatment with a statin started later
in life (3).
CONCLUSIONS
We found that the effect of lower LDL-C on the risk of
CHD mediated by polymorphisms in the NPC1L1 gene,the HMGCR gene, or both is approximately the same
per unit lower LDL-C and log-linearly proportional to
the absolute magnitude of the exposure to lower
LDL-C. We conclude that there appears to be no dif-
ference in the biological effect of lower LDL-C on the
risk of CHD mediated by inhibition of NPC1L1 or
HMGCR. Therefore, lowering LDL-C with ezetimibe, a
statin, or combination therapy with both ezetimibe
and a statin should each reduce the risk of CHD by
approximately the same amount per unit lower LDL-C
and the magnitude of the observed clinical beneﬁt
should be proportional to the absolute magnitude of
the reduction in LDL-C, regardless of which treatment
is used. More generally, our results suggest that the
effect of lower LDL-C on the risk of CHD appears to be
determined by the absolute magnitude of exposure
to lower LDL-C, independent of the mechanism by
which LDL-C is lowered.
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